10 Firms Shine Amid Market Slump

4. Tempus AI Inc. (NASDAQ:TEM)

Tempus AI grew its share prices by 7.23 percent on Monday to end at $61.54 apiece as investor sentiment was fueled by news that it completed the acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

The $600 million acquisition included $375 million in cash payments and $225 million in shares. Of the latter, $100 million will be subject to a lock-up agreement for one year following the transaction.

Tempus AI said Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team.

“This acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies,” said Eric Lefkofsky, founder and CEO of Tempus AI. “We are excited to welcome Ambry to the Tempus team as we work together to improve patient outcomes and transform treatment journeys through the power of technology.”